New York A 11334: Expands collaborative drug therapy management by pharmacists

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A11334 Summary:

BILL NOA11334 

&nbsp

SAME ASNo Same As

&nbsp

SPONSORRules (McDonald)

&nbsp

COSPNSRSteck

&nbsp

MLTSPNSR

&nbsp

Amd §6801-a, Ed L; amd §5, Chap 21 of 2011

&nbsp

Expands collaborative drug therapy management by pharmacists; makes permanent certain provisions relating to authorizing pharmacists to perform collaborative drug therapy management with physicians in certain settings.

Go to top A11334 Actions:

BILL NOA11334 

&nbsp

05/11/2026referred to higher education

Go to topA11334 Committee&nbspVotes:

Go to topA11334 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA11334 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 11334

 IN ASSEMBLY

 May 11, 2026
 ___________

 Introduced by COMMITTEE ON RULES -- (at request of M. of A. McDonald) --
 read once and referred to the Committee on Higher Education

 AN ACT to amend the education law, in relation to expanding collabora-
 tive drug therapy management; and to amend chapter 21 of the laws of
 2011 amending the education law relating to authorizing pharmacists to
 perform collaborative drug therapy management with physicians in
 certain settings, in relation to the effectiveness thereof

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Paragraph d of subdivision 1 and subdivision 4 of section
 2 6801-a of the education law, as amended by chapter 238 of the laws of
 3 2015, are amended to read as follows:
 4 d. "Facility" shall mean: (i) a teaching hospital or general hospital,
 5 including any diagnostic center, treatment center, or hospital-based
 6 outpatient department as defined in section twenty-eight hundred one of
 7 the public health law; [or] (ii) a nursing home [with an on-site pharma-
 8 cy staffed by a licensed pharmacist]; (iii) a physician practice; or
 9 (iv) a facility licensed, certified, or otherwise authorized pursuant to
 10 article thirty-one or article thirty-two of the mental hygiene law,
 11 provided, however, for the purposes of this section the term "facility"
 12 shall not include dental clinics, dental dispensaries, residential
 13 health care facilities and rehabilitation centers.
 14 For the purposes of this section, a "teaching hospital" shall mean a
 15 hospital licensed pursuant to article twenty-eight of the public health
 16 law that is eligible to receive direct or indirect graduate medical
 17 education payments pursuant to article twenty-eight of the public health
 18 law.
 19 4. The existence of a written agreement or protocol on collaborative
 20 drug therapy management and the patient's right to choose to not partic-
 21 ipate in collaborative drug therapy management shall be disclosed to any
 22 patient who is eligible to receive collaborative drug therapy manage-
 23 ment. Collaborative drug therapy management shall not be utilized unless
 24 the patient or the patient's authorized representative consents, in
 25 writing, to such management. If the patient or the patient's authorized

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD15789-01-6

 A. 11334 2

 1 representative consents, it shall be noted on the patient's medical
 2 record. If the patient or the patient's authorized representative who
 3 consented to collaborative drug therapy management chooses to no longer
 4 participate in such management, at any time, it shall be noted on the
 5 patient's medical record. Patient consent to participate in collabora-
 6 tive drug therapy management may be obtained through the same process a
 7 facility currently utilizes to receive general written consent from
 8 patients to receive health care services. In addition, the existence of
 9 the written agreement or protocol and the patient's consent to such
 10 management shall be disclosed to the patient's primary physician and any
 11 other treating physician or healthcare provider.
 12 § 2. Section 5 of chapter 21 of the laws of 2011, amending the educa-
 13 tion law relating to authorizing pharmacists to perform collaborative
 14 drug therapy management with physicians in certain settings, as amended
 15 by section 2 of part P of chapter 57 of the laws of 2024, is amended